Search News
| 85.46 Delayed Data As of Sep 21 |  -0.51 / -0.59%Today’s Change | 72.30 Today|||52-Week Range 94.19 | +1.79% Year-to-Date |
| Should Value Investors Pick Novartis AG (NVS) Stock? Sep 21 / Zacks.com - Paid Partner Content | Is Now a Good Time to Buy Tilray Inc.? Sep 18 / MotleyFool.com - Paid Partner Content |
| NVS vs. AZN: Which Stock Is the Better Value Option? Sep 21 / Zacks.com - Paid Partner Content | Aduro's Cancer Arm & Strong Collaborations Boost Growth Sep 18 / Zacks.com - Paid Partner Content |
| Exelixis' Partner Ipsen Gets Approval for Cabometyx in Canada Sep 20 / Zacks.com - Paid Partner Content | Does Ajovy's Approval Make Teva a Pain-Free Stock to Buy? Sep 18 / MotleyFool.com - Paid Partner Content |
| Eli Lilly Prices Animal Health Unit IPO at $24 Per Share Sep 20 / Zacks.com - Paid Partner Content | Teva's (TEVA) Migraine Drug Ajovy Receives FDA Approval Sep 17 / Zacks.com - Paid Partner Content |
| Cannabis Company Tilray's (TLRY) Shares Up 856% Since July Sep 20 / Zacks.com - Paid Partner Content | Is Artificial Intelligence the Next Big Thing in Biotech? Sep 17 / Zacks.com - Paid Partner Content |
| Previous close | 85.97 |
| Today’s open | 85.16 |
| Day’s range | 85.12 - 85.67 |
| Volume | 2,938,397 |
| Average volume (3 months) | 1,751,278 |
| Market cap | $198.4B |
| Earnings growth (last year) | +17.07% |
| Earnings growth (this year) | +10.12% |
| Earnings growth (next 5 years) | +6.15% |
| Revenue growth (last year) | +1.88% |
| P/E ratio | 14.5 |
| Price/Sales | 4.03 |
| Price/Book | 2.67 |
| Today’s change | Today’s % change | |
|---|---|---|
| MRKMerck | +0.32 | +0.45% |
| ABBVAbbVie | -0.42 | -0.45% |
| PFEPfizer | +0.31 | +0.71% |
| ABTAbbott Laboratories | +0.26 | +0.38% |
| Next reporting date | October 18, 2018 |
| EPS forecast (this quarter) | $1.30 |
| Annual revenue (last year) | $49.4B |
| Annual profit (last year) | $7.7B |
| Net profit margin | 15.69% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer Vasant Narasimhan |
Chief Financial Officer Harry Werner Kirsch |
Corporate headquarters Basel, Basel-stadt (basle Town) |
